Trial Profile
An Open-Label, Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects Under Seizure and Normal Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Diazepam (Primary)
- Indications Epilepsy; Generalised epilepsy; Partial epilepsies; Seizures
- Focus Pharmacokinetics
- Sponsors Neurelis
- 08 Sep 2021 Tmax and AUC of diazepam have been removed from the primary end-points.
- 20 May 2020 According to a Neurelis media release, data from this study will be presented at the American Academy of Neurology.
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology